4//SEC Filing
Patel Sanjiv 4
Accession 0000950170-24-087435
CIK 0001812364other
Filed
Jul 28, 8:00 PM ET
Accepted
Jul 29, 6:37 PM ET
Size
16.4 KB
Accession
0000950170-24-087435
Insider Transaction Report
Form 4
Patel Sanjiv
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-07-26−36,706→ 482,073 totalExercise: $5.04Exp: 2029-04-22→ Common Stock (36,706 underlying) - Exercise/Conversion
Common Stock
2024-07-26$5.04/sh+36,706$184,998→ 802,836 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-07-25−50,000→ 518,779 totalExercise: $5.04Exp: 2029-04-22→ Common Stock (50,000 underlying) - Exercise/Conversion
Common Stock
2024-07-25$5.04/sh+50,000$252,000→ 816,130 total - Sale
Common Stock
2024-07-25$9.16/sh−50,000$458,000→ 766,130 total - Sale
Common Stock
2024-07-26$9.07/sh−36,706$332,923→ 766,130 total
Holdings
- 674,548(indirect: By Trust)
Common Stock
- 687,355(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024.
- [F2]Includes 762,360 shares underlying restricted stock units.
- [F3]This transaction was executed in multiple trades at prices ranging from $9.00 to $9.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]This transaction was executed in multiple trades at prices ranging from $9.00 to $9.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F5]These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F6]The shares underlying this option vested in sixteen (16) equal quarterly installments after April 23, 2019.
Documents
Issuer
Relay Therapeutics, Inc.
CIK 0001812364
Entity typeother
Related Parties
1- filerCIK 0001816210
Filing Metadata
- Form type
- 4
- Filed
- Jul 28, 8:00 PM ET
- Accepted
- Jul 29, 6:37 PM ET
- Size
- 16.4 KB